Mechanism of action of immunomodulatory agents in multiple myeloma.
Immunomodulatory agents (IMiD's) have become an important drug category in the treatment of multiple myeloma. The agents have a complex mechanism of action that influence the microenvironment in the bone marrow. The microenvironment is an essential promotor of disease progression and therefore important in targeting the disease. The article reviews mechanism of action and essential pathways of IMiD's that are important in disease treatment.
Reske
Thomas
T
VA Boston Healthcare System, Boston, MA, USA.
Fulciniti
Mariateresa
M
Munshi
Nikhil C
NC
D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000276:immunology; D013792:Thalidomide / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use
D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D013792:Thalidomide
Ther Clin Risk Manag. 2008 Feb;4(1):129-36
18728702
Blood. 2004 Mar 1;103(5):1787-90
14512311
Cancer Res. 2002 Apr 15;62(8):2300-5
11956087
Oncogene. 2003 Apr 24;22(16):2417-21
12717418
Blood. 1996 Feb 1;87(3):1104-12
8562936
Hematol Oncol Clin North Am. 1997 Feb;11(1):27-42
9081202
J Biol Chem. 2002 May 10;277(19):16639-47
11872748
Blood. 2002 Jun 15;99(12):4525-30
12036884
Clin Cancer Res. 2006 Dec 1;12(23):7165-73
17145842
Cancer Res. 2005 Dec 15;65(24):11712-20
16357183
J Bone Miner Metab. 2009;27(1):16-23
19057841
Semin Hematol. 2005 Oct;42(4 Suppl 4):S3-8
16344099
Nat Rev Cancer. 2002 Dec;2(12):927-37
12459731
Blood. 2003 Aug 15;102(4):1435-42
12714512
Leukemia. 2007 Sep;21(9):1875-84
17611556
Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4082-5
7513432
Leuk Lymphoma. 2008 Jul;49(7):1238-45
18452080
Br J Cancer. 2002 Nov 4;87(10):1166-72
12402158
Blood. 1999 May 1;93(9):3044-52
10216101
Leukemia. 2001 Dec;15(12):1950-61
11753617
Blood. 2004 Dec 15;104(13):4188-93
15319277
Drug Discov Today. 2005 Jan 15;10(2):107-14
15718159
J Immunol. 1997 Jul 1;159(1):487-96
9200490
Oncogene. 2001 Sep 20;20(42):5991-6000
11593406
Apoptosis. 2001 Feb-Apr;6(1-2):47-55
11321040
Exp Eye Res. 1997 Jun;64(6):971-8
9301478
J Cell Biochem. 2007 Jul 1;101(4):950-68
17546631
Br J Haematol. 2007 May;137(3):268-9
17408469
Leukemia. 2008 Oct;22(10):1925-32
18596740
Lancet. 2006 Mar 11;367(9513):825-31
16530576
Hematol Oncol Clin North Am. 2007 Dec;21(6):1071-91, viii-ix
17996589
Blood. 2002 Nov 1;100(9):3063-7
12384400
Mol Med. 1996 Jul;2(4):506-15
8827720
Blood. 2001 Jul 1;98(1):210-6
11418482
Leukemia. 2009 Dec;23(12):2222-32
19741729
Blood. 1999 Mar 1;93(5):1658-67
10029595
J Immunol. 1999 Jul 1;163(1):380-6
10384139
Eur J Biochem. 1998 Jun 15;254(3):439-59
9688254
N Engl J Med. 1999 Nov 18;341(21):1565-71
10564685
Leuk Res. 2006 Jul;30(7):849-58
16494942
J Clin Oncol. 2007 Oct 1;25(28):4459-65
17785703
Blood. 2002 Mar 15;99(6):2162-71
11877293
Blood. 2007 Jul 1;110(1):334-8
17371942
Blood. 2000 Nov 1;96(9):2943-50
11049970